Search clinical trials for: empagliflozin

Total 433 results

Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (SHIELD)

Non-Alcoholic Fatty Liver Disease
Matthieu Pelletier-Galarneau, MD MSc

Not yet recruiting

Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging (SWEET-HEART)

Myocardial Suppression
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
Handok Inc.

Not yet recruiting

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Healthy Volunteers
International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Assiut University

Not yet recruiting

SGLT2 Inhibitors and Perioperative Period

Perioperative Complication
Damanhour University
Tanta University

Recruiting

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Coronary Artery Disease | Type 2 Diabetes

Egypt
Pharma Nueva

Not yet recruiting

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Healthy Vollunteer
Aristotle University Of Thessaloniki

Recruiting

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Cardiovascular Prevention | Tissue Oxygenation | Empagliflozin | SGLT2-Inhibitors | Hematocrit Change

Greece
Boehringer Ingelheim

Recruiting

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

Kidney Disease, Chronic

Korea, Republic of
University of Louisville

Recruiting

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (ARTCAP)

Coronary Artery Disease | Atherosclerosis | Heart Attack

United States
Anita Saraf
The Pittsburgh Foundation

Not yet recruiting

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease (EmpaCHD)

Heart Failure | Adult Congenital Heart Disease

United States
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease (EMPA-PRED)

Heart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease (EMPA-RRED)

Heart Failure With Reduced Ejection Fraction | End Stage Renal Disease on Dialysis
Bio-innova Co., Ltd

Not yet recruiting

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Healthy Subjects
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Ketones, SGLT2, HFrEF

Heart Failure With Reduced Ejection Fraction | Type2diabetes

United States
October 6 University
University of Florida; Beni-Suef University; National Heart Institute, Egypt

Recruiting

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Heart Failure | Genetic Polymorphisms

United States
Medanta, The Medicity, India
Diabetes & Endocrinology Foundation

Recruiting

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

Type 2 Diabetes

India
Assiut University

Not yet recruiting

Treatment of Patients With Diabetic Kidney Disease

Diabetic Kidney Disease
Rigshospitalet, Denmark

Recruiting

EMPagliflozin After Aortic Valve Replacement (EMPAVR)

Aortic Valve Stenosis

Denmark
Amir Moheet

Recruiting

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Cystic Fibrosis | Cystic Fibrosis-related Diabetes

United States
University of Texas Southwestern Medical Center

Recruiting

Polypill for Prevention of Cardiomyopathy (PolyPreventHF)

Type 2 Diabetes | High Blood Pressure

United States
National Taiwan University Hospital

Recruiting

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Ventilator Lung | Heart Failure Acute

Taiwan
Clinical Research Centre, Malaysia
University of Malaya; Ministry of Health, Malaysia

Recruiting

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) (EpiCAD)

Coronary Artery Disease

Malaysia
Rajaie Cardiovascular Medical and Research Center
Tehran Heart Center

Recruiting

Empagliflozin to Prevent Post-Operative Atrial Fibrillation (EMPOAF)

CABG | Post-operative Atrial Fibrillation

Iran, Islamic Republic of
Sohag University

Not yet recruiting

The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

Fatty Liver, Nonalcoholic
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
Washington D.C. Veterans Affairs Medical Center
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Podocyte Specific Proteins (Injury Markers) in African American Veterans With Albuminuric Non-Diabetic Chronic Kidney Disease (NDKD)

Chronic Kidney Diseases

United States
Ain Shams University

Not yet recruiting

Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

Cancer
Medanta, The Medicity, India

Not yet recruiting

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus (EmLina Renal)

Diabetes Mellitus | Kidney Transplant; Complications
University Medical Center Groningen
Boehringer Ingelheim

Not yet recruiting

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (Optimize@Home)

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Complications | Chronic Kidney Diseases | Albuminuria | CKD | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | CKD Stage 4 | CKD Stage 3 | Chronic Kidney Disease Due to Type 2 Diabetes Mellitus | Diabetes Mellitus Type 2 With Proteinuria
Medanta, The Medicity, India

Recruiting

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus (EmLinaRenal)

Diabetes Mellitus | Kidney Transplant; Complications

India
Imperial College London
Royal Brompton & Harefield NHS Foundation Trust

Not yet recruiting

Therapy to Maintain Remission in Dilated Cardiomyopathy (TRED-HF2)

Heart Diseases | Heart Failure | Cardiomyopathies | Cardiomyopathy, Dilated
Liverpool School of Tropical Medicine
Kamuzu University of Health Sciences

Not yet recruiting

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

Malaria,Falciparum | Anemia in Children
Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
China National Center for Cardiovascular Diseases

Recruiting

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Hypertension | Pre-Heart Failure

China
Maastricht University Medical Center

Recruiting

Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction | Microvascular Dysfunction

Netherlands
Chulalongkorn University

Not yet recruiting

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 (TREAT-CRS)

Empagliflozin in Cardiorenal Syndrome Type 1

Thailand
Colorado Prevention Center
Bayer; Saint Luke's Hospital of Kansas City

Not yet recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) (CONFIRMATION)

Heart Failure
McGill University Health Centre/Research Institute...
Diabetes Canada

Recruiting

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

Type 1 Diabetes

Canada
VA Office of Research and Development
VA Pittsburgh Healthcare System; Nashville VA Medical Center; Iowa City VA Health...

Not yet recruiting

Empagliflozin Treatment in Kidney Transplant Recipients (SEKTR)

Type 2 Diabetes | Kidney Transplant

United States
Centre Hospitalier Universitaire Vaudois
University College, London; Great Ormond Street Hospital for Children NHS Foundation...

Not yet recruiting

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Heart Failure

Switzerland, United Kingdom
Vanderbilt University Medical Center

Recruiting

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function (SADIE2)

Obesity | Metabolic Syndrome

United States
Shahid Beheshti University of Medical Sciences

Recruiting

Empagliflozin in Heart Failure Dialysis Patients

Heart Failure | Hemodialysis

Iran, Islamic Republic of
Xinhua Hospital, Shanghai Jiao Tong University...

Recruiting

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Glycogen Storage Disease Type IB

China
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Type 1 Diabetes | Type 2 Diabetes

United States
Jinnah Postgraduate Medical Centre

Not yet recruiting

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Non-Alcoholic Fatty Liver Disease | Type2diabetes

Pakistan
Collegium Medicum w Bydgoszczy

Recruiting

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment (DEMETER)

Metabolic Syndrome

Poland
University of Alabama at Birmingham

Not yet recruiting

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

Obesity | Weight Loss

United States
Central Hospital, Nancy, France

Not yet recruiting

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. (EMPASHOCK)

Cardiogenic Shock

France

Search clinical trials for: empagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations